OKYO Pharma (OKYO) Receivables (2021 - 2026)

OKYO Pharma (OKYO) has reported Receivables for 6 consecutive years, with $380249.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables rose 54.05% year-over-year to $380249.0 in Q1 2026; TTM through Mar 2026 was $380249.0, a 54.05% increase from a year earlier, with the FY2026 full-year figure at $751498.0, up 55.05% from the prior year.
• Receivables was $380249.0 for Q1 2026 at OKYO Pharma, up from $246842.0 in the prior quarter.
• Over five years, Receivables peaked at $933043.0 in Q1 2023 and troughed at $157523.0 in Q1 2024.
• A 5-year average of $511597.8 and a median of $380249.0 in 2026 frame the typical range for Receivables.
• Across the five-year window, Receivables slumped 100.0% in 2022 and jumped 56.7% in 2025, its largest moves.
• Over 5 years, Receivables stood at $840332.0 in 2022, then rose by 11.03% to $933043.0 in 2023, then tumbled by 83.12% to $157523.0 in 2024, then jumped by 56.7% to $246842.0 in 2025, then soared by 54.05% to $380249.0 in 2026.
• The last three Receivables figures came in at $380249.0 (Q1 2026), $246842.0 (Q1 2025), and $157523.0 (Q1 2024), per Business Quant data.